Aortech Share Discussion Threads

[the stigologist] 10/5/2018 09:20

twiddle even

[bones] 10/5/2018 09:04

Parsons, I take your point but it seems the policy of the company is not to be a publicity seeker. It has a requirement under AIM to tell the market twice a year what is going on unless something specific arises. All they said was that once their strategic review is done they would inform us. They know the shareholder base is small and the company is more like a private company that doesn't really (currently) need to be listed.My conclusion is whatever is going on must be fairly material. I do not rule out M&A of some kind given that:1. AOR is a small company that owns valuable IP which makes it a potential target either of itself or its assets.2. M&A activity was hinted at in the previous strategy review mentioned by The Stig a few posts back.They were pretty clear after the settlement was struck in December that their eyes had been opened about their IP, so I can't see that they would fiddle their thumbs.

[parsons4] 10/5/2018 05:51

TS I agree but the time that has elapsed is ridiculous, especially with not one update !! IMHO it can only mean that either they are struggling with their new business plan or the deal is so large and complex that "the legals" are very time consuming. If it were the second you would expect a few "insiders" would have been nibbling by now. Anyway I am sure we will soon find out. This is still one of my largest holdings as at this price with a £2m market cap there should be very little downside whatever is going on.

[the stigologist] 09/5/2018 14:38

Starting to look too cheap (by multiples) at £2m and chart consolidating and setting up well for launchpad type move

I re-read the last Interims. The optionality on offer is far too great for a Company which is

Cashflow positive
Has cash on the balance sheet
Cash makes up a major fraction of it's Market Cap
Great IP royalty/licensing business model
Tightly held by 'Insiders'
Only 5.6m shares in issue
Incredible optionality in massive potential markets such as Breast implants, Heart Valves etc

[mikeh30] 09/5/2018 11:33

37.5/39 so should see a bit of blue.Well bid too.

[semper vigilans] 09/5/2018 10:41

Good point - we will see if there was any cash as part of the settlement?

[bones] 09/5/2018 09:45

Thanks, Stig. I for one look forward to hearing what is in store now that the spat with Foldax is settled. I guess there has to be some kind of strategy, maybe a partnership, around the progression of the heart valve development using Elast-Eon, etc. That has been a long running desire of Aortech. Hopefully, all interested parties are now on the same page.

[the stigologist] 09/5/2018 09:32

Whilst we await the next '5 year plan', reminder of the last one

Business Strategy

In our strategic review last year we identified that the key value driver for the Company was its Intellectual Property comprising material patents and the critical know-how to the manufacturing process.

It was also identified, however, that seeking to achieve a commercial return through volume manufacturing neither recognised nor provided a satisfactory commercial return for the Company's Patents and IP.

As a result, AorTech has focused on generating income from Patent and IP related revenue streams such as milestones payments, licence fees and royalties from customers who incorporate our material into their product line.

We have been actively engaged and continue to be engaged with our customers in restructuring agreements to provide AorTech with future revenues, achieved mainly from royalties.

Your Board continues to examine the potential for achieving a satisfactory return to shareholders on the basis of realising appropriate value for its Polymer business, Patents and IP. However, notwithstanding this potential, your Board is determined to achieve a future revenue stream to enable the company to achieve profitability together with positive cash flow.

The business strategy outlined above provides the basis for AorTech to develop profitably as an IP business with attractive future royalty potential. This strategy does not however preclude the option for the Polymer business to become part of a larger business with the resources to further develop the reach and penetration of the IP into the wider medical devices sector.

[the stigologist] 08/5/2018 17:50

and they've tweeted about Elast-eon

[the stigologist] 08/5/2018 17:48

Not really hiding it

they've had blog posts about it

[25october1969] 08/5/2018 17:38

This is where biometrics are hiding elast-eon and ecsil


hxxp://biomerics.com/products/medical-polymers/

The Quadrasil™ line of thermoplastic silicone polyurethane co-polymers exhibit the properties of both urethane and silicone. Included in our Quadrasil™ family is our standard Quadrasil™ line, Elast-Eon™, and ECSil™.
The Elast-Eon™ family of polymers combines the advantageous properties of both polyurethanes and silicone rubbers into a single material. These materials exhibit the physical and mechanical performance of polyurethanes and a biological stability that surpasses rigid biostable polyurethanes. Elast-Eon™ polymers are widely accepted as being the most biostable of all polyurethane materials and as such are being used in long-term implantation. Elast-Eon™ may be used in applications including:

CRM Devices (e.g. Pacemaker)
Neurostimulation Devices
Electro Signaling Devices
Breast Implants
IUDs
Implantable Joint Interface Coating
Stents
Ear Tubes
Heart Wall Graft

ECSil™ polycarbonate silicone is a family of next generation biomedical polymers. ECSil™ retains the class leading biological stability of Elast-Eon™ while exhibiting superior physical properties across the grade range. ECSil™ is available in a range of mechanical properties, but extends the softer materials to 70 Shore A while still delivering properties many times better than equivalent silicone rubbers. ECSil™ is generally used in applications where the device requires a very high level of mechanical performance. ECSil™ can be used in applications such as:

Blood Glucose Monitoring
Finger Joint
General Orthopedic
Spinal Discs

[mikeh30] 04/5/2018 10:57

That's the way I was looking too

[semper vigilans] 04/5/2018 10:11

No mention of price in the article?

[bones] 04/5/2018 10:07

Thanks Mike. Live link here:



I wonder if there is a use for Elast-Eon or EcSil in "tube extrusion, catheter assembly, final FDA product packaging for sterilization"?

[mikeh30] 04/5/2018 08:38

This acquisition is consistent with Biomerics' strategy to expand and invest in additional production and engineering capabilities to develop a global competitive advantage,"

[mikeh30] 04/5/2018 08:38

https://www.prnewswire.com/news-releases/biomerics-and-atl-technologies-acquire-cri-medical-300638315.htmlBiomerics on acquisition trail.Interesting stuff

[bbr391] 24/4/2018 20:46

News will be the driver .
Until then , seriously parked .

Best of All

[the stigologist] 24/4/2018 14:13

hmm once again as with December the PYC move seems to have woken up some of these smaller plays

[the stigologist] 23/4/2018 15:01

No rush. Sometimes longer the consolidation/sideways move the bigger the ultimate up move. e.g. witness PYC today :-D

[mikeh30] 23/4/2018 14:57

Zzzzzzzz gotta be an update soon. Anyone emailed the board yet?

[bones] 18/4/2018 19:57

Pattern of recent days' selling looks like regular 5k lumps to try not to wreck the quoted prices. Two more late on today then a 25k flourish to finish at any price. I would wager it has been the same seller. Maybe they are done?

[landy90] 18/4/2018 18:25

Stig has pelvic floor weakness but can laugh about it